Concentra Executive Anderson Announces Retirement
Concentra Group announced that Dr. John Anderson, executive vice president and Chief Medical Officer, will retire from Concentra at the end of the year. Dr. Anderson plans to advise the company as part of a consulting arrangement following his planned departure. The company has initiated a formal search for Anderson's successor. "Dr. Anderson has been an invaluable member of the Concentra leadership team for many years and played a central role in establishing our data-driven, outcome-focused approach to delivering occupational health services that has benefited countless patients and employers," said Keith Newton, Chief Executive Officer of Concentra. "On behalf of our board and colleagues, we thank Dr. Anderson for his leadership and lasting impact and wish him the very best in his retirement."
Trade with 70% Backtested Accuracy
Analyst Views on CON
About CON
About the author

- Leadership Transition: Concentra announced that Chief Medical Officer John Anderson will retire at the end of the year, subsequently advising the company, which may impact the strategic direction and quality of healthcare services.
- Career Achievements: Anderson joined Concentra in 1993 and became CMO in 2014, playing a pivotal role in advancing a data-driven approach to occupational health services, enhancing the company's reputation and competitiveness in the industry.
- Company Scale and Impact: Concentra is the largest provider of occupational health services in the U.S., operating 628 health centers and 411 onsite clinics, supporting approximately 53,000 patients daily, highlighting its crucial role in improving the health of America's workforce.
- Future Outlook: Upon retirement, Anderson expressed confidence in the company's future, emphasizing Concentra's commitment to high-quality care, which lays a solid foundation for ongoing growth.
- Earnings Release Schedule: Concentra will release its financial results for the first quarter ended March 31, 2026, on May 7, 2026, after market close, providing investors with crucial financial data and operational insights.
- Conference Call Timing: The company will host a conference call on May 8, 2026, at 9 a.m. Eastern Time, which will be available via live webcast, allowing investors to access real-time information and participate in a Q&A session.
- Participation Details: Investors can join the audio-only version of the webcast by calling toll-free 888-506-0062 or internationally at 973-528-0011, using the participant access code 873704, ensuring widespread dissemination and interaction of information.
- Company Overview: Concentra is the largest provider of occupational health services in the U.S., operating 628 occupational health centers and 411 onsite health clinics, supporting approximately 53,000 patients daily, showcasing its leadership and service capabilities in the industry.
- Strong Financial Performance: Concentra reported Q4 2025 revenue of $539.1 million, a 15.9% year-over-year increase, with full-year revenue reaching $2.2 billion, up 13.9% from 2024, indicating robust market performance and sustained growth potential.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 was $95.3 million, with a full-year adjusted EBITDA of $431.9 million, reflecting EBITDA margins of 17.7% and 20%, showcasing the company's success in cost management and operational efficiency.
- Clear Future Outlook: Management set 2026 revenue targets between $2.25 billion and $2.35 billion, with adjusted EBITDA targets of $450 million to $470 million, demonstrating confidence in future growth and clarity in strategic planning.
- Positive Market Feedback: CEO Newton highlighted that the average total workers' compensation claims cost for those treated by Concentra is 25% lower than non-Concentra providers, with claim durations reduced by 65 days, indicating competitive advantages and improved customer satisfaction.
- Quarterly Dividend Declaration: Concentra Group Holdings has declared a quarterly dividend of $0.0625 per share, maintaining the previous level, which indicates the company's stable cash flow and profitability.
- Yield Information: The forward yield of this dividend stands at 1.06%, reflecting the company's attractiveness in the current market environment, potentially appealing to income-seeking investors.
- Payment Schedule: The dividend will be payable on March 19, with a record date of March 12 and an ex-dividend date also on March 12, ensuring shareholders receive their dividends promptly, thereby boosting shareholder confidence.
- Dividend Growth Potential: By maintaining a consistent dividend policy, Concentra demonstrates its commitment to shareholder returns, which may attract more long-term investors and further enhance the company's market value.
- Earnings Performance Boost: Concentra Group's Q4 earnings reached $34.69 million, translating to $0.27 per share, which marks a significant increase from last year's $21.51 million and $0.17 per share, indicating enhanced profitability.
- Adjusted Earnings Growth: Excluding special items, Concentra reported adjusted earnings of $36.13 million, or $0.28 per share, showcasing the company's sustained growth potential in its core operations.
- Significant Revenue Increase: The company's Q4 revenue rose by 15.9% to $539.08 million, up from $465.04 million last year, reflecting strong market demand and the effectiveness of the company's sales strategies.
- Enhanced Market Competitiveness: With ongoing earnings and revenue growth, Concentra solidifies its market position within the industry, positioning itself for potential market share expansion and increased investor confidence in the future.
- Earnings Performance: Concentra Group Holdings reported a Q4 non-GAAP EPS of $0.28, aligning with market expectations, which indicates the company's stability in profitability despite competitive pressures in the market.
- Revenue Growth: The company reported Q4 revenue of $539.1 million, reflecting a year-over-year increase of 15.9%, showcasing strong demand in the healthcare sector and effective market strategies.
- Strategic Execution: Concentra is flawlessly executing its roll-up strategy, continuously expanding its market share and enhancing its competitiveness in the healthcare industry, which is expected to further drive revenue growth in the future.
- Future Outlook: The company released preliminary results for 2025 and provided guidance for 2026, demonstrating confidence in future growth while offering investors clear financial expectations.








